This handout is for cardiac tamponade — post-rf ablation iatrogenic (pvi / atypical-flutter / steam-pop). Your care team identified this based on: intra-procedural hypotension/bradycardia/arrest in ep lab during pvi, transseptal puncture, or la mapping → catheter perforation; stat ice for confirmation (hrs/ehra 2017 pmid 28506916; cappato care 2013 pmid 23588631).
Other reasons your team may use this plan: audible "steam pop" at ablation tip with sudden ice artifact + impedance drop + new hemodynamic instability → micro-perforation + intramural hemorrhage extending to pericardium (hrs/ehra 2017); post-pvi hemodynamic decompensation within first 24h → late perforation or delayed bleeding (cappato 2013 pmid 23588631); new pericardial effusion on intra-procedural ice or post-pvi echo with hemodynamic concern (hrs/ehra 2017 class i monitoring).
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| normal saline | 500-1000 mL bolus | IV | rapid bolus then reassess | Bridge preload (ESC 2015) |
| norepinephrine | 0.05-0.5 µg/kg/min titrate to MAP ≥65 | IV | continuous | Bridge only — does not address obstruction (Roy JAMA 2007 PMID 17456823) |
| protamine | 1 mg per 100 U residual UFH (max 50 mg single dose); for ACT 300-400 baseline typical PVI dose 25-50 mg | IV | slow IV over 10 min | Standard EP-lab tamponade reversal — PVI uses UFH ACT 300-400 to prevent catheter thrombus; protamine reverses immediately (HRS/EHRA 2017 PMID 28506916; Bhatt 2018) |
| phytonadione | 10 mg IV slow over 10 min | IV | single dose | Vit K reverses warfarin synthesis defect; works over 6-12h (Bhatt Circulation 2018) |
| 4-factor prothrombin complex concentrate | 25-50 U/kg based on INR | IV | single dose | Immediate factor replacement for warfarin reversal in major bleeding (Bhatt Circulation 2018) |
| idarucizumab | 5 g IV (2 × 2.5 g vials) | IV | single dose | RE-VERSE AD (Pollack NEJM 2017 PMID 28793172) — complete dabigatran reversal within minutes; many AF ablation patients on uninterrupted dabigatran |
| andexanet alfa | low dose 400 mg bolus + 4 mg/min × 2h OR high dose 800 mg bolus + 8 mg/min × 2h based on FXa-DOAC dose + timing | IV | bolus + infusion | ANNEXA-4 (Connolly NEJM 2019 PMID 30730782) — anti-FXa reversal; many AF ablation patients on uninterrupted apixaban/rivaroxaban |
| acetaminophen | 650-1000 mg q6h scheduled | PO/IV | q6h | NSAID avoidance in immediate post-drainage period due to bleeding risk; avoid colchicine immediately post-procedure (wound healing not as relevant for percutaneous PVI but extrapolated from CIRCS post-cardiotomy data — for atrial-flutter cases done with surgical maze, classic colchicine timing applies) |
Plan: Post-RF ablation tamponade — emergent drainage + protamine reversal of intra-procedural heparin + pre-procedural-anticoagulant reversal + surgical readiness (HRS/EHRA 2017 PMID 28506916; Bhatt 2018)
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
Cardiology + EP follow-up; echo at 1 wk + 1 mo to confirm resolution; AEF surveillance for 4-6 wk if posterior LA ablation (fever + neurologic symptoms + dysphagia/odynophagia → emergent CT chest with PO contrast or MRI to rule out AEF, mortality >50%; HRS/EHRA 2017 §AEF; Mansour 2018); anticoagulation re-initiation per AF-stroke-risk indication (CHA2DS2-VASc)
Guideline: HRS/EHRA/ECAS/APHRS/SOLAECE 2017 Expert Consensus Statement on Catheter and Surgical Ablation of AF (Calkins HeartRhythm 2017 PMID 28506916) §Complications + 2024 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of AF (Joglar Circulation 2024 PMID 38033089) — current as of 2026-05-15. Cappato 2010/2013 worldwide AF ablation registries (PMID 19996100, 23588631) anchor incidence + mortality data. ESC 2015 pericardial diseases (Adler EHJ 2015 PMID 26320112) §Iatrogenic and Bhatt Circulation 2018 + RE-VERSE AD (Pollack NEJM 2017) + ANNEXA-4 (Connolly NEJM 2019) anchor reversal pathways.